Rimonabant in rats with a metabolic syndrome: good news after the depression

This publication has 12 references indexed in Scilit:

• The cannabinoid receptor‐1 antagonist rimonabant inhibits platelet activation and reduces pro‐inflammatory chemokines and leukocytes in Zucker rats
  British Journal of Pharmacology, 2008
• Biology and therapeutic potential of cannabinoid CB₂receptor inverse agonists
  British Journal of Pharmacology, 2008
• The emerging role of TRPV1 in diabetes and obesity
  Trends in Pharmacological Sciences, 2008
• CB₂-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion
  American Journal of Physiology-Heart and Circulatory Physiology, 2007
• Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
  Hepatology, 2007
• Endocannabinoids and the control of energy balance
  Trends in Endocrinology & Metabolism, 2007
• Obesity—can we turn the tide?
  BMJ, 2006
• Abdominal obesity and metabolic syndrome
  Nature, 2006
• The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism
  Journal of Biological Chemistry, 2001
• Human platelets bind and degrade 2‐arachidonoylglycerol, which activates these cells through a cannabinoid receptor
  European Journal of Biochemistry, 2001